L-Methionine: A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Names and Chemical Identity
L-Methionine is a sulfur-containing essential amino acid. It is known by numerous synonyms including γ-Methylthio-α-aminobutyric acid, (S)-2-Amino-4-(methylthio)butanoic acid, 2-Amino-4-(methylthio)butyric acid, L-2-Amino-4-(methylthio)butyric acid, and abbreviations including Met and L-(-)-Methionine. Its IUPAC name is (S)-2-amino-4-(methylthio)butanoic acid.
Methionine's molecular formula is C₅H₁₁NO₂S, and its side chain is C₂H₇S. L-methionine belongs to the aspartate family of amino acids, which are not synthesized by mammalian cells. It is structurally unique, being composed of a thioether hydrophobic side chain. Methionine is the only sulfur-containing essential amino acid.
L-Methionine exists as two stereoisomers: the biologically active L-form and the mirror-image D-form. Regarding human nutrition, L-methionine is an essential amino acid whereas D-methionine is non-nutritive. A racemic mixture, DL-methionine, is commonly used in animal feed supplementation; DL-Met is a DL racemic mixture of methionine, and can be converted to L-Met under the action of the corresponding enzyme.
The compound is registered in PubChem under Compound ID (CID) 6137. Its full record encompasses chemical names, physical and chemical properties, classification, biological activities, and safety/toxicity information.
1.2 Natural Sources
The essential sulfur-containing amino acid L-methionine is abundant in high biological value protein such as in meat, fish, and dairy products. Plants and animals are both sources of methionine. Plant sources include legumes, whole grains, nuts, seeds, fruits, and green leafy vegetables. Meat (chicken, turkey, beef, and pork), fish, eggs (especially egg whites), and dairy (milk, cheese, and yoghurt) are all animal protein sources. High concentrations of L-methionine are present in meat, eggs, Brazil nuts, and sesame seeds. It is also available in some seeds of plants and cereals. However, most vegetables and fruits hold low levels of L-methionine.
1.3 Commercial Production and Common Forms
Methionine is currently industrially produced worldwide in large amounts and is of considerable commercial importance. Methionine is employed in many fields, including pharmaceutical, health and fitness products, but particularly as a feedstuff additive, where both the racemic and the enantiomerically pure form may be used. On an industrial scale, methionine is produced chemically via the Bucherer-Bergs reaction, a variant of the Strecker synthesis, in which starting substances methylmercaptopropionaldehyde, hydrogen cyanide, ammonia, and carbon dioxide are reacted to give 5-(2-methylmercaptoethyl) hydantoin, which is subsequently hydrolysed by alkali and then liberated by acid neutralisation.
As a dietary supplement, L-methionine is available in several forms: oral capsules and tablets (typically 500 mg per unit), as a loose powder, and in some combination products. L-methionine is more and more used in food, pharmaceutical, cosmetics, feed additives, and many other fields. A combination product containing acetaminophen 500 mg and methionine 100 mg has been available in clinical settings: a combination of acetaminophen (500 mg) and methionine (100 mg) is available in the United Kingdom (Paradote®) to prevent the onset of acetaminophen poisoning through the maintenance of high glutathione levels in the liver. The methionine in this formulation contains both the L-isomer and the D-isomer.
2. Historical and Traditional Use
L-Methionine as an isolated compound does not have a classical phytomedicine or traditional herbal history equivalent to botanical remedies, as it is an amino acid whose identity as such was established through 20th-century biochemistry. The amino acid homocysteine, an important downstream metabolite of methionine, was first identified by Butz and du Vigneaud during their investigation of decomposition products of methionine. Homocysteine was first identified 90 years ago by Butz and du Vigneaud during their investigation of decomposition products of methionine.
From a clinical history standpoint, L-methionine's pharmaceutical and supplemental use developed primarily in the 20th century. The agent L-methionine, which has been on the market for some 30 years, has a different mode of action from other urological drugs, achieving its effect by the acidification of urine. Its use as a urinary acidifier and in the management of urinary tract pathologies thus predates the broader nutraceutical supplement era by several decades.
L-methionine has been used for many years as an aid in the treatment of urolithiasis and as a prevention of further occurrence of struvite crystal formation by the acidification of the urine. Similarly, its use as an antidote in acetaminophen (paracetamol) overdose has been documented in clinical medicine since the 1970s, particularly in the United Kingdom, where it was incorporated into combination pharmaceutical products.
3. Key Biochemical Constituents and Mechanisms of Action
3.1 Role in Protein Synthesis and as the Initiator Amino Acid
L-Met is crucial for cell functioning as it plays an essential role in the initiation of translation of protein biosynthesis and takes part in various metabolic processes inside the cell. In eukaryotic cells, every protein synthesis event begins with methionine; it is the universal "start" codon amino acid.
3.2 The Methionine Cycle and S-Adenosylmethionine (SAMe)
The most pharmacologically and biochemically significant role of L-methionine lies in its conversion to S-adenosylmethionine (SAMe, also written SAM). The first step in methionine catabolism is the generation of S-adenosylmethionine (SAMe), the principal biological methyl donor, in a reaction catalyzed by methionine adenosyltransferase (MAT). SAMe is synthesized in the liver from L-methionine and adenosine triphosphate (ATP), playing a crucial role as a primary methyl donor required for numerous biological functions.
L-methionine participates in various metabolic processes and serves as a precursor for the synthesis of S-adenosylmethionine (AdoMet), which is involved in the methylation of DNA molecules and phospholipids, as well as in maintaining genome stability. Under normal conditions, most of the SAMe generated is used in transmethylation reactions.
When SAMe donates its methyl group in transmethylation reactions, it is converted to S-adenosylhomocysteine (SAH), which is then hydrolyzed to homocysteine. Homocysteine is a key junction metabolite in methionine metabolism. It suffers two major metabolic fates: transmethylation catalyzed by methionine synthase or betaine homocysteine methyltransferase and transsulfuration catalyzed by cystathionine β-synthase leading to cystathionine.
3.3 The Transsulfuration Pathway and Glutathione Synthesis
The transsulfuration pathway is a metabolic pathway where transfer of sulfur from homocysteine to cysteine occurs. The pathway leads to the generation of several sulfur metabolites, which include cysteine, glutathione (GSH), and the gaseous signalling molecule hydrogen sulfide (H₂S).
In hepatocytes, homocysteine can undergo conversion to cysteine via the transsulfuration pathway, a two-step enzymatic process catalyzed by cystathionine β-synthase (CBS) and cystathionase, both requiring vitamin B6. The cystathionine is subsequently converted to cysteine, a precursor of glutathione. Glutathione is the body's primary intracellular antioxidant, and SAMe is a known precursor to glutathione, which establishes the antioxidant potential of SAMe in liver injury and disease.
Starting from homocysteine, a sulfur-containing amino acid derived from methionine via the methionine cycle, the transsulfuration pathway supports the biosynthesis of cysteine and other downstream products, such as taurine, serine, reduced glutathione and the gasotransmitter hydrogen sulfide (H₂S).
The liver plays a central role in methionine metabolism, as up to half of the daily intake of methionine is catabolized in the liver. Transsulfuration is regulated by stimulation of cystathionine β-synthase and inhibition of methylene tetrahydrofolate reductase in response to changes in the level of S-adenosylmethionine, and this promotes homocysteine degradation when methionine availability is high.
3.4 Remethylation: The Methionine Cycle
Homocysteine does not accumulate irreversibly; it can be recycled back to methionine. Homocysteine can be remethylated to form methionine via methionine synthase (MS), which requires folate and vitamin B12, and betaine homocysteine methyltransferase (BHMT), which requires betaine. This cyclical interconversion — methionine → SAMe → SAH → homocysteine → methionine — is known as the methionine cycle or one-carbon metabolic cycle, and it is central to methylation biology throughout the body.
3.5 Downstream Metabolite Synthesis
Beyond the methionine cycle and transsulfuration, methionine acts as a precursor of such compounds as choline (lecithin) and creatine and at the same time is used as a synthetic raw material for cysteine and taurine. S-Adenosyl-L-methionine is derived from L-methionine and plays a role in providing methyl groups in the human body and is also involved in the synthesis of various neurotransmitters in the brain.
3.6 Urinary Acidification Mechanism
L-methionine is an amino acid which is metabolized to sulfate and hydrogen ions by the liver, thereby conferring an acid load onto the kidney and in theory can reduce urinary pH. This sulfur oxidation pathway is what underpins the clinical application of L-methionine in urinary acidification. Urinary sulfate excretion, a direct marker for the metabolism of L-methionine, and ammonium excretion, which reflects the increase in net acid production, increased significantly after L-methionine administration.
4. Scientific Evidence by Area of Use
4.1 Urinary Tract Health: Acidification, Infection Prevention, and Urolithiasis
Mechanism and Rationale
The essential amino acid L-methionine is a potential compound in the prophylaxis of recurrent or relapsing urinary tract infection due to acidification of urine. Acidifying the urine creates an environment less favorable for urease-producing bacteria (such as Proteus) and reduces the formation of struvite (magnesium ammonium phosphate) kidney stones, which form in alkaline urine.
Human Clinical Evidence: Urinary pH and Stone Formation
Twelve healthy subjects were studied while consuming a standardized diet for 6 days. Day 5 was considered the control day. On day 6, participants received 1,500 mg L-methionine at 9 AM. On both days, 24-hour fractional urine collections were obtained. After single-dose administration of L-methionine, 24-hour fractional urinary pH decreased to values between 5.98 and 6.32. The study showed that urinary acidification can be obtained following oral administration of almost physiological doses of L-methionine.
A broader literature review found that for urinary acidification, the most effective interventions were ammonium chloride, methionine, and high protein diet, respectively. L-methionine has been suggested as a possible preventative therapy by acidifying the urine, as demonstrated in long-term and short-term studies.
Regarding struvite stone management specifically, doses of 1,500 to 3,000 mg/day in humans reduced the mean pH values of the urine of 19 subjects from 7.5 to 5.5 in a study of struvite stone formers. A 2016 study in the journal Urology concluded that physiological doses of L-methionine effectively decrease urinary pH and the risk of struvite and calcium phosphate stone formation in healthy subjects. However, randomized controlled trials are needed to test whether administration of L-methionine is equally effective for decreasing urinary pH and the risk of stone formation in phosphate stone formers.
Human Clinical Evidence: Recurrent UTI Prevention
One study aimed to study the metabolism of L-methionine and homocysteine, and to assess whether there are differences between patients with chronic urinary tract infection and healthy control subjects. Using a randomized placebo-controlled double-blind intervention study with a cross-over design at Friedrich Schiller University of Jena, Germany, eight female patients with chronic urinary tract infection and 12 healthy women (controls) received 500 mg L-methionine or a placebo three times daily for 4 weeks.
A multi-center observational study assessed a food supplement containing L-methionine combined with Hibiscus sabdariffa and Boswellia serrata extracts: adjuvants or alternatives to antibiotics in urinary tract infections (UTIs) during pregnancy seem advisable because of possible fetal stress. The study assessed the effectiveness of a food supplement containing L-methionine and Hibiscus sabdariffa L. and Boswellia serrata Roxb. extracts as a treatment for symptomatic UTIs in pregnancy, in which pregnant patients with symptomatic cystitis were screened in three different clinical centers. Note that because the supplement in that study contained multiple active ingredients, L-methionine's independent contribution cannot be cleanly isolated from the results.
Neurogenic Bladder: Evidence Assessment by IQWiG
The German Institute for Quality and Efficiency in Health Care (IQWiG) searched for randomized controlled studies in which one group of patients with neurogenic bladder disorders received L-methionine and comparators received a different drug, non-drug therapy, or placebo, with the aim of treating or preventing UTIs, urinary stones, or optimizing antibiotic effects. The literature search showed that only one study including a total of 89 patients with paraplegia fulfilled these criteria. In this study, L-methionine was compared to placebo. Similarly high rates of adverse events occurred in both treatment groups, so that there is no proof that L-methionine causes harm, but equally, neither benefit nor harm was established with certainty. The body of high-quality randomized trial evidence for L-methionine in this population thus remains extremely limited.
Encrusted Uropathy: Case Report
A published case report documented that a patient with encrusted uropathy (EU) was treated with chronic L-methionine as oral acidifying treatment, in whom almost complete resolution of the calcifications was achieved. This was the first case report in the literature to show that oral urinary acidification is a treatment option for calcifications in EU. The patient was discharged on oral L-methionine 500 mg twice daily, and 12 months later the encrustations had almost disappeared. Such case-level evidence is preliminary and cannot be generalized.
4.2 Chronic Bacterial Prostatitis
Acidification of urine has been used as a technique to treat and prevent symptomatic urinary tract infections. Current pharmacological research in the field of bacterial prostatitis focuses on combinations of available antibiotics with prostatic microenvironmental modifiers for the prevention and treatment of chronic bacterial prostatitis (CBP) clinical recurrences. A study aimed to assess whether, in addition to antibiotic therapy, acidification of urine and prostatic microenvironment decreases CBP recurrences. This represents an emerging area of interest; however, the quality and quantity of clinical evidence remains limited.
4.3 Liver Health and Metabolism
Background: Methionine Deficiency in Liver Disease
SAM synthesis is suppressed in chronic liver disease (CLD), and therefore, considerable interest has been focused on utilizing SAMe for reducing disease severity. However, clinical research on methionine supplementation remains insufficient and the results are controversial.
SAMe (the Downstream Metabolite) and Liver Disease
Most clinical liver research uses SAMe (S-adenosylmethionine) rather than L-methionine directly, but since SAMe is synthesized from L-methionine, the biochemical rationale is linked. It has been well established that SAMe is the principal methyl donor in methyltransferase reactions and that SAMe supplementation restores hepatic glutathione (GSH) deposits and attenuates liver injury.
A 2015 systematic review and meta-analysis (Guo et al., PLoS ONE) examined 12 RCTs from 11 studies involving 705 patients with chronic liver disease. The results showed that twelve RCTs from 11 studies, which examined 705 patients, were included. For liver function, certain results demonstrated significant differences between the levels of total bilirubin (TBIL) and aspartate transaminase (AST). However, no studies identified significant differences regarding alanine transaminase (ALT) levels. An analysis of adverse events and long-term prognosis also indicated no significant differences between the SAMe and placebo groups. In a subgroup analysis of gravidas and children, several of the included data indicated a significant difference in pruritus score. This represents moderate-quality evidence with mixed outcomes, and the authors noted insufficient evidence to make firm conclusions about the efficacy of SAMe in chronic liver disease.
A 2024 systematic review on SAMe specifically for liver health similarly concluded that the beneficial effects of SAMe in specific liver diseases has not been fully established in humans.
High-Dose Methionine and Liver Toxicity (Animal Data)
In contrast to the hepatoprotective narrative, animal data at high doses reveal a different picture. In a rat study, male Wistar albino rats received orally L-methionine at 1 g/kg/day for 21 days. Methionine treatment increased homocysteine, total oxidant status (TOS), oxidative stress index (OSI), malondialdehyde (MDA), and protein carbonyls (PC), but decreased total antioxidant status (TAS), glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) with 20S proteasome activities. Liver proteins AST, ALT, LDH, ALP, total bilirubin, and CRP were increased but albumin was decreased. Liver histology was also altered. An increase in liver TNF-α and IL-6 levels was observed. These findings indicated that methionine supplementation associated oxidative stress and proteasome dysfunction, causing hepatotoxicity and inflammation in rat. These findings are from an animal model with very high doses and should not be extrapolated directly to typical human supplemental doses, but they do underscore the non-linear dose-response relationship.
4.4 Acetaminophen (Paracetamol) Overdose Treatment
This is one of the best-documented clinical applications of L-methionine. In acetaminophen poisoning, methionine prevents the breakdown products of acetaminophen from damaging the liver. Mechanistically, acetaminophen overdose generates the hepatotoxic metabolite NAPQI, which depletes hepatic glutathione; L-methionine, as a glutathione precursor, replenishes this antioxidant defense. Research shows that receiving methionine by mouth or intravenously seems to be effective for treating acetaminophen poisoning. Treatment should begin as quickly as possible, but must start within 10 hours of acetaminophen overdose.
The documented clinical dose protocol is: 2.5 grams of methionine every 4 hours for 4 doses to prevent liver damage and death. Methionine must be given within 10 hours of taking the acetaminophen. An alternative dosing reference states the generally recommended dosage of L-methionine is 2.5 g immediately, followed by 2.5 g at 4-hour intervals. This is a medical intervention to be carried out under professional supervision, not a self-care supplement use.
4.5 Cancer: The Methionine Dependence Phenomenon
A substantial and growing body of preclinical evidence concerns the relationship between methionine availability and cancer cell biology — with the focus being on restricting methionine, not supplementing it, as a potential anti-cancer approach.
Studies in 1976 demonstrated that although intracellular methionine levels in cancer cells are normal or even elevated, their proliferation remains absolutely dependent on exogenous methionine, a contradictory occurrence known as the 'Hoffman effect'. Methionine is an essential amino acid with many key roles in mammalian metabolism such as protein synthesis, methylation of DNA, and polyamine synthesis. Restriction of methionine may be an important strategy in cancer growth control, particularly in cancers that exhibit dependence on methionine for survival and proliferation. Methionine dependence in cancer may be due to one or a combination of deletions, polymorphisms, or alterations in expression of genes in the methionine de novo and salvage pathways.
Many tumors develop a metabolic dependency due to the lack of a working methionine salvage pathway. Approximately 15% of cancers, including glioma and pancreatic cancer, show a loss of Methylthioadenosine Phosphorylase (MTAP).
Preclinically, methionine is important for cancer cell growth and metabolism. A growing body of evidence indicates that methionine restriction inhibits cancer cell growth and may enhance the efficacy of chemotherapeutic agents. Preclinical models have shown promise with dietary methionine restriction significantly suppressing tumor growth in multiple models, including both solid tumors and blood cancers.
Regarding human clinical data on methionine restriction: clinical studies using methionine-restricted diets showed mixed effects, but endpoint data were mainly focused on efficacy of plasma methionine reduction. Plasma methionine levels fell by about 50% and patients lost an average of 0.5 kg weight per week. Combination of methionine restriction with 5-fluorouracil in preoperative high-stage gastric cancer patients showed a striking effect on tumor pathology when tumors were examined after surgery. Methionine restriction may thus enhance the response to chemotherapeutics in a synergistic fashion. These clinical observations are preliminary and have not yet established clinical practice guidelines.
Important note: The cancer-related literature concerns restricting methionine as a therapeutic strategy. This is the opposite direction from supplementation. Supplementing L-methionine to cancer patients is not supported by this body of literature and could theoretically counteract methionine restriction strategies.
4.6 Aging and Longevity Research
Methionine restriction (MetR) extends lifespan across different species and exerts beneficial effects on metabolic health and inflammatory responses. It was shown that restriction of a single amino acid, methionine, can mimic the effects of dietary restriction and extend lifespan in various model organisms.
Regarding late-life intervention in mice: to investigate the efficacy of targeting methionine metabolism for healthspan improvement in advanced age, dietary MetR was initiated in 18-month-old C57BL/6J mice. MetR significantly improved neuromuscular function, metabolic health, lung function, and frailty. However, in a human trial (NCT04701346), an 8-week MetR intervention showed no significant impact on epigenetic clocks. Human evidence in this area remains very preliminary.
4.7 Neurotransmitter Synthesis and Neurological Context
L-Methionine's conversion to SAMe has implications for neurotransmitter methylation. S-Adenosyl-L-methionine derived from L-methionine is involved in the synthesis of various neurotransmitters in the brain. However, in experimental contexts, high-dose L-methionine administration demonstrated complex effects: L-methionine had no behavioral effects in normal humans and failed to increase concentrations of SAM (methyl donor) in human or rat blood, while increasing rat liver levels more than fivefold. This highlights the complexity of translating biochemical mechanisms into predictable clinical effects.
4.8 Cardiovascular-Related Methylation and Homocysteine
Through its metabolic conversion to homocysteine, L-methionine is indirectly relevant to cardiovascular risk. Homocysteine has been associated with diverse diseases including neural tube defects, cardio- and cerebrovascular disease and, more recently, dementia and Alzheimer's Disease. The most common disruption of the transsulfuration pathway leads to hyperhomocysteinemia (HHcy), a well-known risk factor for the development of cardiometabolic diseases and other pathological conditions.
Supplemental L-methionine, when given at high doses, raises homocysteine levels in plasma, which is a recognized safety concern (see Section 6). The relationship is not straightforward in the opposite direction either — supplementing methionine to lower cardiovascular risk has not been established in the clinical literature reviewed here.
5. Body Systems and Health Areas Associated with L-Methionine
- Urinary system: Urinary acidification, UTI prophylaxis, struvite urolithiasis prevention, and encrusted uropathy.
- Hepatic system: Liver methionine metabolism as a foundation of hepatic function; SAMe-mediated glutathione replenishment and methylation in liver disease. The liver catabolizes a large fraction of dietary methionine and is the primary site of the methionine cycle.
- Cardiovascular system: Indirect relevance through the homocysteine pathway; high dietary methionine may elevate plasma homocysteine, a cardiovascular risk marker.
- Nervous system: SAMe derived from methionine participates in neurotransmitter methylation; methionine's role as a precursor for choline and phospholipid synthesis has neurological implications. High-dose methionine can exacerbate psychopathological symptoms in some individuals.
- Antioxidant defense: Via the transsulfuration pathway, methionine is the ultimate precursor for cysteine and subsequently for glutathione, the body's principal endogenous antioxidant.
- Cancer biology: Cancer cells exhibiting the methionine dependence phenotype are a target of research; the context here is restriction, not supplementation.
- Aging and longevity: Methionine restriction has been studied as a longevity intervention in model organisms; human evidence is extremely preliminary.
- Connective tissue and skin: As a sulfur amino acid, methionine contributes sulfur to keratin proteins (hair and nails) and to collagen cross-linking, though specific clinical evidence for supplementation in this area is limited.
6. Dosage Forms and Clinically Reported Dosages
6.1 Dosage Forms
L-Methionine is commercially available in free-form oral capsules and tablets, typically in unit strengths of 500 mg. It is also available as a bulk powder for incorporation into formulations. DL-methionine is available as a one-a-day food supplement in 500 mg oral tablet form. In the pharmaceutical context, it has been formulated in combination with acetaminophen (e.g., Paradote® in the UK) and has been administered intravenously in clinical settings for acetaminophen poisoning.
6.2 Dosages Reported in Studies
- Urinary acidification (single dose, healthy subjects): 1,500 mg L-methionine administered as a single dose.
- Struvite stone management (long-term): 1,500 to 3,000 mg/day in humans, which reduced the mean urinary pH of 19 subjects from 7.5 to 5.5.
- Recurrent UTI prevention (cross-over study): 500 mg L-methionine three times daily (1,500 mg/day) for 4 weeks.
- Encrusted uropathy (case report): 500 mg twice daily (1,000 mg/day).
- Acetaminophen poisoning treatment: 2.5 grams every 4 hours for 4 doses (total 10 g), initiated within 10 hours of overdose.
- Methionine loading test (research tool): A "loading dose" of methionine (0.1 g/kg) has been given, and the resultant acute increase in plasma homocysteine has been used as an index of susceptibility to cardiovascular disease.
- Norwegian Food Safety Authority (VKM) risk assessment: The Norwegian Food Safety Authority requested a risk assessment of intakes of 200, 300, 500, 600, and 700 mg L-methionine per day from food supplements. The VKM concluded that it maintains a guidance level of 210 mg methionine per day from supplements.
- WHO estimated requirement: According to the World Health Organization, the optimal daily dose of L-methionine is about 13 milligrams per kilogram of body weight.
7. Safety Considerations and Drug/Nutrient Interactions
7.1 Homocysteine Elevation
The primary and most extensively documented safety concern with L-methionine supplementation is its potential to raise plasma homocysteine levels. The role of methionine as a precursor of homocysteine is the most notable cause for concern. Longer-term studies in adults have indicated no adverse consequences of moderate fluctuations in dietary methionine intake, but intakes higher than 5 times normal resulted in elevated homocysteine levels.
A "loading dose" of methionine (0.1 g/kg) has been given, and the resultant acute increase in plasma homocysteine has been used as an index of susceptibility to cardiovascular disease. Although this procedure results in vascular dysfunction, this is acute and unlikely to result in permanent damage. At extreme doses, a 10-fold larger dose, given mistakenly, resulted in death.
In addition to impairing protein synthesis, homocysteine is also directly toxic to the endoplasmic reticulum, activates glutamate receptors, and damages DNA. Elevated homocysteine has been associated with cardiovascular disease, neural tube defects, and neurological conditions.
7.2 B-Vitamin Interaction and Mitigation
These effects of methionine on homocysteine and vascular function are moderated by supplements of vitamins B-6, B-12, C, and folic acid. This is biochemically consistent: folate and vitamin B12 are required for the remethylation of homocysteine back to methionine via methionine synthase, and vitamin B6 is required for the transsulfuration pathway enzymes. Coadministration of B-vitamins is therefore relevant when methionine supplementation raises homocysteine.
High doses of L-methionine have been reported to affect folate status: administration of 8 grams of L-methionine to adult subjects for four days caused a greater than 30% reduction in serum folate levels.
7.3 Neuropsychiatric Caution in Schizophrenia
Although methionine is known to exacerbate psychopathological symptoms in schizophrenic patients, there is no evidence of similar effects in healthy subjects. Large doses of methionine (e.g., 20 g/day for 5 days) might cause confusion, disorientation, delirium, agitation, and listlessness in people with schizophrenia.
7.4 Pediatric Safety
In infants, methionine intakes of 2–5 times normal resulted in impaired growth and extremely high plasma methionine levels, but no adverse long-term consequences were observed. Extra caution is warranted when considering supplemental methionine in infants or young children outside of clinical supervision.
7.5 Liver Toxicity at High Doses
As reviewed in the animal data under Section 4.3, supraphysiological doses of methionine can cause oxidative stress and hepatic injury in rodent models. Despite methionine being mainly metabolized in the liver and acting as an antioxidant, being the precursor for glutathione (GSH) synthesis, and the principal methyl donor for important biological reactions such as DNA methylation and protein synthesis, when it is consumed in excess, it can cause pathophysiological effects. Translating specific dose thresholds from animal data to humans requires caution.
7.6 Potential Drug Interactions
L-methionine is a precursor to SAMe. SAMe should not be taken with monoamine oxidase inhibitors (MAOIs), including carbex, Eldepryl, Marplan, Nardil, and Parnate. Given that L-methionine is converted to SAMe in vivo, this interaction class is biochemically relevant to methionine supplementation as well, though direct clinical trial data on L-methionine specifically in combination with MAOIs are not available in the retrieved literature.
7.7 General Tolerability
Nutritional and metabolic studies have employed amounts of methionine, including the D and DL isomers, both below and above the requirement and have not reported adverse effects in adults and children. L-methionine is well tolerated at regular doses; mildly common side effects include nausea, vomiting, drowsiness, excitability, dizziness, and low blood pressure.
8. Evidence Summary and Strength of Evidence
The following is an honest characterization of the strength of evidence for each major use area:
- Urinary acidification (mechanism): Well-established biochemical mechanism; supported by small controlled human studies. Evidence is consistent but predominantly from small and non-randomized trials.
- Struvite urolithiasis / UTI prevention: Clinical use of long standing; some supporting human data, but large high-quality randomized controlled trials are lacking. Evidence is preliminary to moderate.
- Acetaminophen overdose treatment: Strongest clinical evidence base. Shown effective in clinical studies when administered within 10 hours; accepted clinical practice in some countries. Evidence is moderate to strong for this specific emergency use.
- Liver disease: Clinical evidence is primarily for SAMe (the downstream metabolite), not L-methionine itself. Meta-analysis of SAMe shows mixed results. Evidence is mixed and insufficient for definitive recommendations.
- Cancer: Methionine restriction has an intriguing preclinical rationale; pilot human data are very limited and mixed. Not applicable to methionine supplementation. Evidence is very preliminary.
- Aging/longevity: Primarily animal model data; single human epigenetic clock study showed no effect. Evidence is preclinical and preliminary.
- Neuropsychiatric applications: Evidence is weak and includes risks in vulnerable populations. Not recommended as a supplement in this context based on available data.
References
Go back